Seeking Alpha

Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device

WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of TangenX® ...
GEN

Downstream Bottlenecks are Slowing mAbs Manufacturing: This New TFF Tech Can Help

For decades, therapeutic monoclonal antibody (mAb) production relied on traditional batch-based manufacturing using stainless steel systems. But as biopharmaceutical pipelines grow to meet rising ...
Seeking Alpha

Repligen: The Hidden Gem In Single-Use Solutions For Biopharma Manufacturing

Repligen, a leading company in biological drug manufacturing, has seen significant growth with sales increasing from $141 million in FY17 to $802 million in FY22, largely due to their single-use ...
Business Insider

Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand

WALTHAM, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into an ...
Business Insider

Analysis on the World's $1.59B Tangential Flow Filtration Market, 2019-2024 - Increasing Adoption of Single-use Technologies and GAMP Guidelines Trigger Growth

Dublin, Jan. 15, 2020 (GLOBE NEWSWIRE) -- The "Tangential Flow Filtration Market by Product (TFF System, Membrane Filter), Application (Bioprocess, Viral Vector Purification), Technique ...